- Home
- LQDA vs PTEN Comparison
LQDA vs PTEN Comparison
Compare LQDA & PTEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LQDA
- PTEN
- Stock Information
- Founded
- LQDA 2004
- PTEN 1978
- Country
- LQDA United States
- PTEN United States
- Employees
- LQDA N/A
- PTEN N/A
- Industry
- LQDA Biotechnology: Pharmaceutical Preparations
- PTEN Oil & Gas Production
- Sector
- LQDA Health Care
- PTEN Energy
- Exchange
- LQDA Nasdaq
- PTEN Nasdaq
- Market Cap
- LQDA 2.5B
- PTEN 2.1B
- IPO Year
- LQDA 2018
- PTEN 1993
- Fundamental
- Price
- LQDA $25.00
- PTEN $5.48
- Analyst Decision
- LQDA Strong Buy
- PTEN Buy
- Analyst Count
- LQDA 9
- PTEN 10
- Target Price
- LQDA $32.11
- PTEN $7.90
- AVG Volume (30 Days)
- LQDA 2.2M
- PTEN 7.7M
- Earning Date
- LQDA 11-12-2025
- PTEN 10-22-2025
- Dividend Yield
- LQDA N/A
- PTEN 5.90%
- EPS Growth
- LQDA N/A
- PTEN N/A
- EPS
- LQDA N/A
- PTEN N/A
- Revenue
- LQDA $19,322,000.00
- PTEN $5,019,214,000.00
- Revenue This Year
- LQDA $405.58
- PTEN N/A
- Revenue Next Year
- LQDA $373.93
- PTEN N/A
- P/E Ratio
- LQDA N/A
- PTEN N/A
- Revenue Growth
- LQDA 30.20
- PTEN N/A
- 52 Week Low
- LQDA $9.68
- PTEN $5.12
- 52 Week High
- LQDA $29.94
- PTEN $9.58
- Technical
- Relative Strength Index (RSI)
- LQDA 45.82
- PTEN 45.64
- Support Level
- LQDA $25.34
- PTEN $5.40
- Resistance Level
- LQDA $28.00
- PTEN $5.70
- Average True Range (ATR)
- LQDA 1.32
- PTEN 0.26
- MACD
- LQDA -0.70
- PTEN -0.00
- Stochastic Oscillator
- LQDA 0.50
- PTEN 34.43
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
About PTEN Patterson-UTI Energy Inc.
Patterson-UTI Energy Inc is one of the substantial land rig drilling contractors in the United States. Its 2023 merger with NexTier greatly expanded its pressure pumping operations, as well, and the firm now controls nearly 20% of the North American market for drilling and completions services. The company operates under three reportable business segments: (i) drilling services, (ii) completion services, and (iii) drilling products. It also provides directional drilling services and tool rental services in united states onshore oil and gas basins.